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ScienceDirectHuman vaccine development remains challenging because of
the highly sophisticated evasion mechanisms of pathogens for
which vaccines are not yet available. Recent years have
witnessed both successes and failures of novel vaccine design
and the strength of iterative approaches is increasingly
appreciated. These combine discovery of novel antigens,
adjuvants and vectors in the preclinical stage with
computational analyses of clinical data to accelerate vaccine
design. Reverse and structural vaccinology have revealed
novel antigen candidates and molecular immunology has led to
the formulation of promising adjuvants. Gene expression
profiles and immune parameters in patients, vaccinees and
healthy controls have formed the basis for biosignatures that
will provide guidelines for future vaccine design.
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Introduction
Vaccines are generally considered one of the most
impressive success stories of medicine [1]. In all docu-
mented instances they have reduced the targeted infec-
tious disease remarkably. The success of currently
available vaccines is based on their ability to induce
antibodies that block or neutralize infectious agents or
their products [1]. Antibody-mediated protection is not
sufficient in all infectious diseases. The major contagious
Open access under CC BY license.Current Opinion in Immunology 2014, 28:18–26 killers of today for which we do not yet have vaccines are
restrained to some extent not only by antibodies but also
by cell-mediated immunity. There is currently a strong
clinical development pipeline for novel vaccines against
infectious diseases. These candidates have entered
clinical trials based on evidence for protective efficacy
in animal models, or, in the case of malaria and some other
infections, in a human challenge model [2]. However,
their development has proceeded without knowledge of
the correlates of vaccine-induced protection and bio-
markers or a biological signature (a custom-made compi-
lation of different biomarkers) that can predict reduced
disease incidence. Ideally, clinical trials generate suffi-
cient data to allow definition of a biosignature that can be
used to predict vaccine efficacy and safety of novel
candidates [3,4] (see Figure 1).
Challenges in human vaccine development
Challenges are faced at all stages of vaccine research and
development (R&D) including: shortening the time of
discovery of vaccine candidates, production and clinical
development; ensuring that vaccines reproduce appropri-
ately native antigens and that the immune response
induced is of adequate strength and quality for efficient
protection; and predicting at early stages safety and ef-
ficacy of vaccine candidates. Novel technologies devel-
oped in recent years can diminish these challenges:
genomics and proteomics for the vaccine antigen discov-
ery; structural biology to redesign broadly protective
antigens; synthetic technologies to accelerate vaccine
production; adjuvants and immunopotentiators to tailor
the appropriate protective immune responses; systems
biology and other computational methods to predict the
safety and the efficacy of vaccines. In the following
sections, examples of these technologies and their appli-
cations will be discussed.
Vaccine target discovery
The potential of vaccine target selection has increased
significantly by the sequencing of whole microbial gen-
omes. This approach, named ‘reverse vaccinology’,
started from the MenB genome, for which conventional
approaches had only limited success [5], and focused on
those proteins predicted to be surface exposed or
secreted. Candidate antigens were identified based on
their ability to induce bactericidal antibodies, which were
known to correlate with protection against disease. This
procedure shortened the time of vaccine target discovery
from decades to a few years, and allowed the identifi-
cation of antigens which were completely unknownwww.sciencedirect.com
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‘Life cycle’ of modern vaccine development comprising iteration of basic research, vaccine trial, clinical study of natural infection and modeling by
computational analysis. Vaccine development against HIV/AIDS, malaria and TB starts from basic research providing proof of concept for a novel
vaccine candidate. Valid candidates are introduced into clinical trial, which will not only provide information about safety and efficacy but also reveal
informative biosignatures. In parallel, clinical studies on naturally infected and diseased individuals can provide information about disease-related
biosignatures. Computational analysis and modeling will generate new hypotheses, which can be validated by basic research. This iteration can lead
to further vaccine improvement.before. Three antigens plus outer membrane vesicles
were tested in clinical trials in adults, adolescents and
young children with satisfactory safety profile, high
immunogenicity [6], and the ability to cover the majority
of MenB strains globally [7]. Results of these studies
allowed the European Medicine Agency to approve the
first vaccine against MenB in 2012 (commercial name:
Bexsero1) [8].
Reverse vaccinology is now applied to a wide variety of
other important pathogens [9]. The concomitant use of
genomics, bioinformatics, proteomics, and protein arrays
can accelerate identification of vaccine targets and the
subsequent vaccine development process [10].
The challenge of vaccine preparation
A major component of the MenB vaccine, the factor H
binding protein (fHbp), induces strong protective anti-
bodies. This antigen, however, has more than 500 amino
acid variants [11] that do not induce cross-protective
immunity. The ideal candidate antigen would be ablewww.sciencedirect.com to induce protective antibodies against all the allelic
variants of the fHbp. Elucidation of the 3D structure
of the antigen revealed protective epitopes in each of the
variants. Chimeric molecules were designed to contain
the identified epitopes in correct conformation. Many of
them elicited broadly protective antibodies and one has
been selected for further studies [12].
Structure-based information is being exploited for
rational design of vaccines against viruses. Information
about the structure of the F protein of respiratory syncy-
tial virus (RSV) allowed design of a novel F protein in
which the protective antigenic site could be stabilized.
Immunization of mice and monkeys with the F protein
containing the stabilized neutralizing site induced pro-
found levels of protective antibodies [13]. Similarly, the
cryo-electron microscopy reconstruction and structural
model of the human immunodeficiency virus (HIV)
gp140 trimer complexed with a broadly neutralizing
antibody has now provided insights into the trimer assem-
bly, the interactions between gp140 and gp41, and theCurrent Opinion in Immunology 2014, 28:18–26
20 Vaccinesinteraction with the CD4 binding site and with neutraliz-
ing antibodies. This paves the way for the development of
structure-based broadly protective vaccines against HIV
[14,15].
Purified proteins are poorly immunogenic and require the
use of adjuvants for the induction of effective responses.
Toll-like receptor (TLR) agonists are promising vaccine
adjuvants and a TLR-4 agonist has been approved in a
vaccine against human papilloma virus [16]. Other adju-
vants are emulsions containing a core of biodegradable
lipids. MF59 [17] and AS03 [18] have been approved with
pandemic and seasonal influenza vaccines (MF59) or with
pandemic influenza vaccines (AS03). These adjuvants not
only increase antibody titers, they also modify the quality
of the antibody response in terms of both breadth of the
strains recognized and the repertoire of B-cell epitopes, as
exemplified by MF59 with H5N1 and seasonal subunit
vaccines [19]. The MF59 adjuvant drives the antibody
response towards the HA1 subunit of the hemagglutinin
(HA), and in particular to the receptor binding site, and
much less to the HA2 moiety, suggesting a role of these
phenomena in the enhanced efficacy and effectiveness of
the MF59-adjuvanted vaccines in infants and the elderly
[20,21,22].
Vaccines against influenza pandemic must become avail-
able prior to the pandemic. During the last H1N1 pan-
demic, mass vaccination was implemented only when
transmission already declined [23]. A prompt response
to a pandemic has become feasible due to in vitro syn-
thesis of genomes [24]. As a prerequisite, sequences of the
viruses isolated must be provided as soon as they are
available. A combination of enzymatic, cell-free assembly
techniques with enzymatic error correction allows rapid
and accurate synthesis of genes that are then used to
transfect cell lines qualified for vaccine manufacturing,
from which viruses can be rescued for vaccine prep-
aration. This process takes as few as five days with the
recovery of synthetic viruses antigenically identical to the
wild-type viruses. This synthetic process has been suc-
cessfully used to generate influenza strains including
seasonal as well as H1N1, H3N2, H5N1 and H7N9 [25].
Predictive biosignatures of vaccine safety and
efficacy
As discussed below, some recent late stage clinical
vaccine trials have unexpectedly shown either a complete
[26,27] or partial [28] lack of efficacy, or raised safety
concerns [26]. Biosignatures of safety and efficacy could
be used in pre-clinical studies to prioritize available
candidates, and in early clinical development to avoid
later failure. Parameters may be identified retrospectively
[27], but post hoc analyses may identify misleading
chance correlations. An alternative approach is to use
vaccines in translational studies to dissect-out mechan-
isms of reactogenicity and efficacy, and such an approachCurrent Opinion in Immunology 2014, 28:18–26 was taken in an HIV vaccine efficacy trial [29]. This can
be applied to human and animal models, in which whole
blood or separated cell population gene expression, multi-
plex cytokine responses, as well as cellular and humoral
immune responses are integrated.
Application of biosignatures to predict
influenza vaccine efficacy
With influenza vaccines, older adults have suboptimal
responses, and using a systems approach Furman et al.
[30] identified an age-related antibody epitope that pre-
dicted the response, possibly by inhibitory memory CD4+
T cells and apoptotic pathways. Observations from lim-
ited human samples can be explored in animal models,
and apoptosis-deficient mice did exhibit poor serologic
responses [30]. Franco et al. found a correlation between
influenza antibody responses and apoptosis gene expres-
sion [31]. In this case T cell-mediated apoptosis of target
cells, together with mechanisms involved in antigen
presentation, membrane trafficking and intracellular
transport were also identified. Tan et al. [32] observed
that upregulation of genes related to proliferation and
immunoglobulin genes segregated high and low vaccine
responders. These correlations would have been missed
by conventional, single-gene level approaches. Querec
et al. [33] also found that whereas molecules in the
integrated stress response predicted antiviral CD8 T cell
responses to influenza vaccines, an independent signature
involving B cells predicted neutralizing antibody
responses.
Harmonization of systems vaccinology
approaches
A challenge for the systems approach is the diversity of
strategies for integrating and analyzing extremely large
sets of high-throughput data. Small numbers of samples,
repeated or single measures of heterogenous parameters
and outcomes, may also lead to contradictory correlations.
Harmonization of analytical tools, reporting of data, and
experimental conditions is needed [34]. Liquet et al.
[35] combined a multilevel analysis with the usual multi-
variate approach to analyze data. Whereas the discrimi-
nant multilevel analysis identified subsets of related
genes, an integrative multilevel analysis revealed clusters
of highly correlated genes and cytokines. This highlights
that the re-analysis of data from a single trial using
different strategies can yield significantly greater infor-
mation. Different vaccine antigens or adjuvant systems
are likely to induce different innate and adaptive
responses, making extrapolation from different trials chal-
lenging. Obermoser et al. [36] detected significant
differences in genes responding to a protein subunit
influenza vaccine versus a conjugate polysaccharide
pneumococcal vaccine. Differences have also been
described between live and non-living vaccines [37].
Applying ‘modules’ of responder genes identified in
inflammatory diseases, two significant challenges arisewww.sciencedirect.com
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module based on infection or inflammatory states may be
misleading for vaccine trials. Different gene expression
patterns of inflammation were found in mice and humans
caused by trauma or burn injury [39]. Secondly, gene
modules complicate comparison between published
results if the modules contain different genes [37].
Systems vaccinology for biosignatures of
reactogenicity
A practical application of a systems approach was the
retrospective identification of underlying factors respon-
sible for an increase in febrile reactions associated with a
specific trivalent influenza vaccine [40]. The investi-
gators integrated human, animal, cell line and primary cell
culture experiments with gene profiles and cytokine
readouts. A combination of the introduction of three
entirely new influenza strains, and differences in the
manufacturing processes were identified as the probable
cause of the unexpected reactogenicity. This opens the
possibility to screen vaccine antigen combinations for
reactogenicity using an ‘omic’ approach [34].
Update on HIV vaccine trials
Improved biomedical strategies are slowly impacting the
HIV epidemic, as shown in recent trends of lower in-
fection rates in some at-risk populations [41]. However,
an end to the HIV pandemic will likely require wide-
spread immunization with an effective vaccine. After
more than two decades of clinical evaluation, no single
vaccine regimen has demonstrated sufficient efficacy to
advance to licensure [42,43]. Concepts tested in efficacy
trials include recombinant bivalent HIV-1 gp120 mono-
mers formulated in alum designed to induce binding and
neutralizing antibodies (VAXGEN003 and VAXGEN004
trials) [44,45], recombinant adenovirus (Ad) serotype 5
(Ad5) vectors encoding HIV-1 genes to induce antiviralTable 1
Accelerating HIV vaccine development building on the RV144 trial out
Strategy 
Post-RV144 Phase III licensure trial in Sub-Saharan Af
1 clade C gene inserts and envelope pr
Improved pox virus vectors with prime-b
T cell immunity CMV vectors to induce potent and pers
Mosaic adenovirus and pox vectors to i
Broad-neutralizing
antibodies
Structure-based immunogen designs re
B-cell ontogeny designs to guide specifi
repertoires.
Immunoprophylaxis Mixtures of HIV broadly-reactive mAbs.
Genetic immunization with vectors enco
Improve durability Alternative adjuvant-protein formulations
Optimized prime-boost regimens, includ
Notes: CMV, cytomegalovirus CMV; HIV, human immunodeficiency virus; 
www.sciencedirect.com CD8+ T cells (Step and Phambili trials) [26,46], and
prime-boost regimens to induce antibodies and T cells
(RV144 and HVTN 505 trials) [47,48].
The low-level efficacy (31%) demonstrated in the RV144
Thai trial with the canarypox vector and bivalent gp120 in
alum prime–boost regimen suggests that a protective
vaccine against HIV acquisition may be possible [48].
Enhancing the level and duration of protection seen in
the RV144 trial is a major goal in clinical vaccine devel-
opment, and public–private partnerships to accelerate
product development and testing in regions with the high-
est HIV incidence rates are underway (Table 1). Current
plans include a licensure trial in Sub-Saharan Africa using
canarypox and subunit envelope protein immunogens that
express antigens from HIV-1 clade C, the most common
subtype circulating in Sub-Saharan Africa, as well as a series
of phase IIb research studies to assess new pox vectors and
other immunogens expressing HIV-1 subtype C antigens
that may improve upon the RV144 regimen and/or poten-
tially induce protection by alternative mechanisms. The
design of these studies will efficiently determine vaccine
safety, efficacy and correlates of immunity to better inform
which regimens to advance to licensure trials and to guide
new vaccine designs.
The HIV vaccine field faced disappointment earlier this
year with the failure of the HVTN 505 phase IIb trial
[47], which evaluated a DNA prime-recombinant Ad5
boost HIV vaccine regimen to assess efficacy in reducing
either the rate of HIV-1 acquisition or post-infection
viremia in 2504 at-risk US men or transgender women
who have sex with men. Unlike previous Ad5/HIV vaccine
studies, both vaccines in this regimen encoded env genes,
and induced both strong HIV-specific CD4+ (62%) and
CD8+T cell (64%) response rates and anti-Env IgG (100%)
to the vaccine strain envelopes and preferentially to thecome and alternative strategies
Designs
rica evaluating RV144 type regimen (ALVAC + bivalent gp120) using HIV-
otein.
oost strategies in phase IIb trials in Sub-Saharan Africa.
istent effector memory T cells.
mprove the breadth and depth of T-cell epitopes recognized.
sembling viral spike and/or distinct neutralizing epitopes.
c clonal lineages, circumvent autoimmunity, and select for B-cell
ding broadly-reactive nAbs.
.
ing DNA plasmid as a prime before the protein boost.
mAbs, monoclonal antibodies; nAbs, neutralizing antibodies.
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22 Vaccinesgp41 region. Of note, anti-Env V1-V2 IgG response rates
were substantially lower than observed in the RV144 trial,
and whether this finding is relevant to the lack of efficacy in
the HVTN 505 trial remains unclear.
Although no significant difference in infection rates be-
tween the vaccine and placebo groups was observed in the
HVTN 505 trial, 41 infections occurred in the vaccine and
31 in the placebo group. Taken together with greater
infection rates in the Step and Phambili trials testing the
Merck Ad5/HIV trivalent vaccine, these data raise con-
cerns about safety and have prompted longitudinal follow
up of HVTN 505 subjects, a meta-analysis of infection
rates in Ad5-vectored HIV-1 vaccinees, and ongoing
experimental studies to understand mechanisms that
may contribute to potential enhancement of infection.
Because Ad-specific CD4+ T cells induced following
natural Ad infections and Ad5 vector immunizations
recognize epitopes across multiple Ad serotypes [49],
one hypothesis is that intercurrent Ad infections, com-
monly detected in mucosal sampling [50], may activate
Ad-specific T cells recognizing cross-reactive epitopes
and increase the number of HIV-1 target cells in the
mucosa. Results from these studies may have implica-
tions in future decisions concerning use of Ad5 and Ad
vectors of other serotypes as vaccines for HIV and other
pathogens in HIV-1-uninfected study participants at risk
for HIV-1 infection.
Update on TB vaccine trials
TB vaccine design is in the unique situation that a com-
parator already exists. As part of the Expanded Program onTable 2
News from preventive tuberculosis vaccine candidates in clinical trial
Candidate Construct Status of clinical dev
VPM1002 rBCGDureC::hly Phase I completed (saf
immunogenic), phase II
MVA85A MVA expressing Rv3804
(Ag85A)
Phase IIb completed (s
immunogenic in target 
no efficacy)
H1 Rv1886 (Ag85B) + Rv3875
(ESAT-6) fusion protein in
adjuvant IC31 or CAF01
Phase I completed (saf
immunogenic)
MVA85A MVA expressing Rv3804
(Ag85A)
Phase IIb ongoing (safe
immunogenic in target 
Ad5HUAG85A Human Ad 5 expressing
Rv3804 (Ag85A)
Phase I completed (saf
immunogenic)
M72 Rv1196 + Rv0125 fusion
protein in adjuvant AS01
Phase IIa completed (s
immunogenic in target 
Notes: Ad, adenovirus; Ag, antigen; AS01E, liposomal-based, surface-activ
Gue´rin; CAF01, liposome-based lipoid MINCLE ligand; IC31, cationic antim
ium tuberculosis; MVA, modified Vaccinia Ankara; rBCG, recombinant BC
Current Opinion in Immunology 2014, 28:18–26 Immunisation (EPI), the vaccine Bacille Calmette-Gue´rin
(BCG) has been administered more than 4 billion times. It
protects against severe extrapulmonary forms of infant TB
but not against pulmonary TB in any age group, which
represents the vast majority of cases and main source of
spreading [51]. Hence, vaccine candidates aimed at repla-
cing BCG need to perform better with respect to efficacy
and/or safety than BCG.
The TB vaccine portfolio comprises recombinant live
vaccines for prime instead of BCG, as well as recombinant
viral vectors expressing Mycobacterium tuberculosis (Mtb)
antigens and adjuvant formulations of Mtb antigens for
heterologous boost following BCG [51–54]. The most
advanced viable recombinant vaccine in clinical trial,
VPM1002, is a recombinant BCG (Table 2), which will
soon complete a phase IIa trial in infants. Vakzine Projekt
Management (VPM) sponsored two phase I trials, which
demonstrated safety and immunogenicity of VPM1002
[55]. Adjuvanted protein vaccine candidates against TB
have mostly been developed by Statens Serum Institut
(SSI) and by GlaxoSmithKline (GSK) (Table 2). One of
the first vaccines to enter clinical trial, the H1 vaccine
from SSI, comprising a fusion protein of two antigens in
the adjuvant Intercell (IC)31, was found to induce strong
immune responses as late as 30 weeks after administration
[56]. GSK have comprehensively analyzed their protein–
adjuvant vaccine candidate M72, by varying the formu-
lation of the vaccine. Although the early formulation
M72F protein in adjuvant system (AS)02 proved both
safe and immunogenic [52,55,57,58], it was further
improved to become the final construct M72 in AS01,s
elopment Type Target population
e and
a ongoing
Viable rBCG for
preexposure
Prime vaccine for infants, to
replace BCG
afe and
population,
Viral vector for
preexposure
Heterologous booster
vaccine for BCG-vaccinated
infants
e and Protein adjuvant for
preexposure
Heterologous booster
vaccine for BCG-vaccinated
individuals
 and
population)
Viral vector for
preexposure
Heterologous booster
vaccine for BCG-vaccinated
adolescents and adults
e and Viral vector for
preexposure
Heterologous booster
vaccine for BCG-vaccinated
individuals
afe and
populations)
Protein adjuvant for
preexposure and
postexposure
Heterologous booster
vaccine for BCG-vaccinated
individuals
e saponin plus Toll-like receptor (TLR)-4 ligand; BCG, Bacille Calmette–
icrobial peptide plus Toll-like receptor (TLR)-9 ligand; Mtb, Mycobacter-
G.
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without prior exposure to Mtb [59]. Notably, high fre-
quencies of multifunctional T cells were induced by M72
in AS01 [60]. This vaccine qualifies for pre-exposure and
post-exposure administration.
Currently, two types of viral vectors are being exploited
for TB vaccination: Ad as potent CD8 T cell inducer
[61], and modified Vaccinia Ankara (MVA) virus, which
preferentially stimulates CD4 T cells [27] (Table 2). A
phase I trial with an Ad5 vector expressing an antigen of
Mtb not only revealed its safety and immunogenicity,
but also assessed effects of preexisting antibodies
directed against the vector [61]. Pre-existing antibodies
could cause rapid elimination of the Ad5-based vaccine
thus reducing its efficacy. Although the study did
not support this apprehension, these and other side
effects of Ad-based vaccines remain a concern (see also
above).
Disappointingly, the phase IIb trial, with the MVA85A
vaccine based on MVA-expressing an antigen of Mtb
[27], given as a heterologous booster on BCG prime to
infants, revealed no evidence of superior protection [27].
However, the vaccine proved safe and the study, com-
prising nearly 3000 infants, proved the feasibility of
performing large-scale TB vaccine trials in Sub-Saharan
Africa [27]. In parallel, this vaccine is currently under-
going a phase IIb trial in adults after results of a phase IIa
trial demonstrated its safety and immunogenicity in indi-
viduals independent of their HIV and Mtb exposure status
[62].
TB biosignatures
Only 10% of those who are infected with Mtb develop
disease during their lifetime. The vast majority remain
healthy but latently infected. Biosignatures that can pre-
dict risk of disease would be helpful for stratification of
study participants with high TB risk for vaccine trials,
leading to reduced size and duration of phase IIb/III
clinical trials. Data from vaccine trials, comprising a
sufficiently high proportion of protected versus nonpro-
tected individuals, should be harnessed for defining cor-
relates of vaccine-induced protection. This approach,
which has been spear-headed in the arena of HIV vacci-
nation [42,43,48,63], could soon be realized in the area
of TB with increasing vaccine candidates entering phase
IIb trials.
In parallel, the availability of the BCG vaccine provides
an opportunity to analyze vaccine-induced protection. A
longitudinal study exploiting canonical immune markers
in BCG-vaccinated infants, who developed TB, failed to
identify a BCG-induced immune correlate of protection
against TB [64]. Intriguingly, this study questioned the
long-held belief that IFN-g suffices as biomarker of
protection.www.sciencedirect.com Ongoing longitudinal studies are comparing blood tran-
scriptome profiles in household contacts of recently diag-
nosed TB cases, with the aim to identify a biosignature
that can predict risk of TB. One ongoing study is analyz-
ing >4000 household contacts of newly diagnosed TB
cases at different sites in Africa (http://www.biomarkers-
for-tb.net/); the other ongoing study has enrolled >6000
adolescents from a highly endemic area in South Africa
[65,66].
Clinical malaria vaccine development
Malaria remains a major public health threat [67]. A
malaria vaccine can play an important role in controlling
the disease in endemic regions. Hope has been raised by
the RTS,S recombinant sporozoite vaccine given in AS01.
Many trials have shown its immunogenicity, tolerability,
and efficacy in various age groups [68]. Recently, results
have been reported from a large multicentric phase III
trial carried out at 11 centers in 7 African countries, with
more than 15 000 enrolled children. In the first part of the
study involving 6000 children (5–17 months old), the
efficacy of 3 doses of the RTS,S/AS01 vaccine against
clinical malaria during the 14 months after the first dose
varied between 50% and 55%, and between 45% and 47%
against severe malaria [69]. In the second part of the
study in infants 6–12 weeks of age receiving the vaccine
together with the EPI vaccines, the efficacy against
clinical malaria and against severe malaria dropped to
about 30% or 26%, respectively [70]. Several reasons may
account for this drop including: the younger age of these
children as compared to those of the first part of the study,
the potential interference between RTS,S/AS01 and
vaccines of the EPI, the pre-existing immune status
towards the hepatitis B vaccine, the possibility that ef-
ficacy varied from one site to another.
The possibility that the efficacy of the RTS,S/AS01
vaccine may vary with the intensity of malaria trans-
mission has been evoked by another study conducted
in Kenya and Tanzania [71]. In this smaller study (about
220 5–17 month-old children) the efficacy against clinical
malaria was about 30% over a period of 4 years, with 43%
during the first year, and 0.4% during the fourth year. The
efficacy was higher in children with a lower malaria-
exposure index (45%) than in children with a higher
malaria exposure index (16%) [71]. These studies
suggest that on the one hand a recombinant subunit
vaccine such as RTS,S/AS01 provides some efficacy
against clinical and severe malaria, and on the other hand
further improvements are necessary to achieve long-term
protection by large-scale vaccination in EPI-vaccinated
young children in highly endemic areas.
An alternative approach has been reported recently,
namely the immunization with non-replicating live atte-
nuated sporozoites given intravenously to healthy volun-
teers followed by challenge through the bites of infectiousCurrent Opinion in Immunology 2014, 28:18–26
24 Vaccinesmosquitoes [72]. All six volunteers receiving the highest
dose of sporozoites (1.35  105) five times, and 6 out of 9
receiving the same dose four times, did not develop any
signs of malaria. Protected individuals had higher titers of
anti-sporozoite antibodies and had higher frequencies of
sporozoite-specific CD4+ and CD8+ T cells in the per-
ipheral blood, especially CD8+ T cells producing IFN-g,
[72]. Further studies will be needed to validate these
findings in larger sample sizes and to determine the
duration of protection. The feasibility of five intravenous
injections of live-attenuated sporozoites for mass vacci-
nation campaigns in malaria-endemic areas may be diffi-
cult, and strategies to simplify this regimen yet retain its
protective response will be required.
Concluding remarks
Although, development of new vaccines still has a long
way to go, recent advances in antigen identification,
adjuvant development and vector design have brought
forward the preclinical vaccine R&D pipeline. These
advancements are complemented by recent accomplish-
ments in human vaccinology including rational design of
biosignatures, which, by predicting risk of disease as well
as vaccine safety and efficacy, can be harnessed for future
improvement of novel vaccine candidates. Thus, an
iterative combination between wet-lab, in silico analyses,
and clinical studies represents the best way to accelerate
development of vaccines needed for control of major
infectious diseases (Figure 1). Even though the first
generation of vaccine candidates may not provide satis-
factory efficacy, comparative analyses of host responses in
protected versus unprotected study participants will
reveal information for further improvement of next-
generation vaccines. To harness novel information arising
from data analysis of ongoing vaccine trials adoptive
vaccine protocols would be best suited.
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